Cannabis Cultivators Keep Growing in October
The medical marijuana market is catching fire in the United States. Less than two weeks into the month of October, MedMen Enterprises (CSE: MMEN) has notched up four deals, and market giant Tilray, Inc. (NASDAQ: TLRY) has announced one. MedMen, based in Culver City, California, is a leading cultivator, producer and retailer of state-sanctioned cannabis in the United States. At the beginning of October, it operated 18 licensed cannabis facilities in California, Nevada and New York, but that list keeps growing. Two of its recent targets are in Illinois, one in Arizona and one in California. The largest of the MedMen deals (to disclose a price) was its acquisition of PharmCann LLC, one of the... Read More »
Allergan Doubles Down on Aesthetics
September 14 was a big day for Allergan plc’s (NYSE: AGN) medical aesthetics business. The company announced its acquisition of Bonti, Inc., a privately held clinical-stage biotech that develops novel, fast-acting neurotoxin programs for aesthetic and therapeutic applications. Later that same day, Allergan hosted a Medical Aesthetics Day in New York, at which its chief commerical officer, Bill Meury, said the company expects the unit to generate between $7 billion and $8 billion in sales by 2025. The business unit generated $3.8 billion in 2017. Allergan’s Medical Aesthetics unit includes the famous neurotoxin Botox (onabotulinumtoxinA), which was first approved in 1989 and... Read More »
Summertime Sales from Novartis
It’s been a busy summer for Novartis AG (NYSE: NVS). The Swiss drug-maker has sold off a few assets, one at a loss. On August 31, Mylan NV (NYSE: MYL) acknowledged that it paid $463 million for Novartis’ cystic fibrosis products. Novartis sold the worldwide rights to commercialize its cystic fibrosis products TOBI Podhaler (tobramycin inhalation powder) and TOBI (tobramycin solution for inhalation). Mylan expects to pay $240 million this year, with the rest coming later. Then on September 6, Novartis announced the sale of certain assets in its Sandoz U.S. portfolio, specifically the Sandoz dermatology business and generic oral solids portfolio. It comprises approximately 300... Read More »Emergent BioSolutions Surges
Emergent BioSolutions Inc. (NYSE: EBS) waited until August to announce its first transactions of 2018, but its stock has been rising all year. On August 9, we reported the company acquired specialty vaccine maker PaxVax, Inc. for $270 million. EBS followed that up on August 28 with a $635 million deal for Adapt Pharma, maker of Narcan® (naloxone HCI) Nasal Spray, the only FDA-approved nasal form of naloxone indicated for the emergency treatment of opioid overdose. Upon closing, Emergent will acquire Narcan and a development pipeline of new treatment and delivery options to address opioid overdose. Narcan is expected to generate revenues of $200 million and be accretive to adjusted net... Read More »
Connecticut Cannabis Company Sold to Tuatara Capital
Tuatara Capital didn’t travel far to find its latest investment. While several companies recently have targeted Florida medical cannabis growers (and their licenses), the New York City-based cannabis investor took a drive up I95 to bag Connecticut Pharmaceutical Solutions (CTS). CTS is a licensed medical cannabis cultivator in the state of Connecticut. It manufactures pharmaceutical-grade medical cannabis products, including dried flower, extracted concentrates, vaporizers, tinctures, oral tablets and sprays, and topical treatments. Tuatara Capital is a specialized alternative investment manager founded in 2014 to support the legal cannabis industry. It currently manages more than... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
